DK1268480T3 - 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer - Google Patents

8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer

Info

Publication number: DK1268480T3
Authority: DK; Denmark
Prior art keywords: xanthine; isoquinoline; quinoline; pde5 inhibitors; derivatives
Prior art date: 2000-04-07

Application number

DK01940294T

Other languages

Danish (da)

English (en)

Inventor

Gurdip Bhalay

Stephen Paul Collingwood

Robin Alec Fairhurst

Sylvie Felicite Gomez

Reto Naef

David Andrew Sandham

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2001-04-05

Publication date

2004-03-15

2001-04-05 Application filed by Novartis Ag filed Critical Novartis Ag

2004-03-15 Application granted granted Critical

2004-03-15 Publication of DK1268480T3 publication Critical patent/DK1268480T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Psychiatry (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

DK01940294T 2000-04-07 2001-04-05 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer DK1268480T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0008694.2A GB0008694D0 (en)	2000-04-07	2000-04-07	Organic compounds
PCT/EP2001/003909 WO2001077110A1 (fr)	2000-04-07	2001-04-05	Derives 8-quinolinxanthine et 8-isoquinolinxanthine comme inhibiteurs pde 5

Publications (1)

Publication Number	Publication Date
DK1268480T3 true DK1268480T3 (da)	2004-03-15

Family

ID=9889516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01940294T DK1268480T3 (da)	2000-04-07	2001-04-05	8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer

Country Status (29)

Country	Link
US (1)	US20030171384A1 (fr)
EP (1)	EP1268480B1 (fr)
JP (1)	JP3869725B2 (fr)
KR (1)	KR100526094B1 (fr)
CN (1)	CN1176922C (fr)
AR (1)	AR028531A1 (fr)
AT (1)	ATE253576T1 (fr)
AU (2)	AU7392101A (fr)
BR (1)	BR0109855A (fr)
CA (1)	CA2403514C (fr)
CZ (1)	CZ20023305A3 (fr)
DE (1)	DE60101158T2 (fr)
DK (1)	DK1268480T3 (fr)
ES (1)	ES2210169T3 (fr)
GB (1)	GB0008694D0 (fr)
HU (1)	HUP0300565A3 (fr)
IL (1)	IL152078A0 (fr)
MX (1)	MXPA02009903A (fr)
MY (1)	MY119238A (fr)
NO (1)	NO20024741L (fr)
NZ (1)	NZ521361A (fr)
PE (1)	PE20020228A1 (fr)
PL (1)	PL212407B1 (fr)
PT (1)	PT1268480E (fr)
RU (1)	RU2269529C2 (fr)
SK (1)	SK14282002A3 (fr)
TR (1)	TR200400185T4 (fr)
WO (1)	WO2001077110A1 (fr)
ZA (1)	ZA200207956B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US7019010B2 (en) *	2001-09-27	2006-03-28	Novertis Ag	Combinations
BR0311760A (pt) *	2002-06-12	2005-03-29	Hoffmann La Roche	Composto, pró-droga de um composto, processo para a preparação do composto, composições farmacêuticas que compreendem o mesmo, sua utilização e método de tratamento de diabetes do tipo 2
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CN102964347B (zh) *	2002-08-21	2015-11-18	勃林格殷格翰制药两合公司	8-[3-氨基-哌啶-1-基]-黄嘌呤化合物，其制备方法及作为药物制剂的用途
CN100361992C (zh) *	2003-02-19	2008-01-16	霍夫曼-拉罗奇有限公司	用作pepck抑制剂的磺酰胺取代的黄嘌呤
US7148229B2 (en)	2003-02-19	2006-12-12	Hoffman-La Roche Inc.	Sulfonamide substituted xanthine derivatives
US7247639B2 (en) *	2003-06-06	2007-07-24	Endacea, Inc.	A1 adenosine receptor antagonists
KR100658080B1 (ko) *	2003-08-26	2006-12-15	비오이 하이디스 테크놀로지 주식회사	백라이트 조립용 지그
TW200605893A (en) *	2004-02-12	2006-02-16	Novartis Ag	Use of organic compounds
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005243149A1 (en) *	2004-05-08	2005-11-24	Novartis International Pharmaceutical Ltd.	1-Aryl-4-substituted isoquinolines
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
US7601723B2 (en) *	2005-02-25	2009-10-13	Pgx Health, Llc	Pyridyl substituted xanthines
US20070004745A1 (en) *	2005-03-25	2007-01-04	Schering-Plough Corporation	Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ZA200804550B (en)	2005-11-09	2009-08-26	Combinatorx Inc	Methods, compositions, and kits for the treatment of medical conditions
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
EP2167057A1 (fr) *	2007-06-13	2010-03-31	Bayer HealthCare AG	Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN102361557A (zh) *	2009-03-26	2012-02-22	Mapi医药公司	制备阿格列汀的方法
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (fr)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combinaison thérapeutique
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX2013009575A (es) *	2011-02-18	2014-10-14	Exonhit Therapeutics Sa	Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
CA2841552C (fr)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Quinazolines substituees, la preparation de celles-ci et l'utilisation de celles-ci dans des compositions pharmaceutiques
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (fr)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2014071044A1 (fr) *	2012-11-01	2014-05-08	Allergan, Inc.	Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
WO2017211979A1 (fr)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinaisons de linagliptine et de metformine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2531085A1 (fr) *	1982-07-28	1984-02-03	Adir	Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
FR2558162B1 (fr) *	1984-01-17	1986-04-25	Adir	Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
TW252044B (fr) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
AU4501199A (en) *	1998-06-03	1999-12-20	Almirall Prodesfarma S.A.	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
GB9828340D0 (en) *	1998-12-22	1999-02-17	Novartis Ag	Organic compounds

2000
- 2000-04-07 GB GBGB0008694.2A patent/GB0008694D0/en not_active Ceased
2001
- 2001-04-05 ES ES01940294T patent/ES2210169T3/es not_active Expired - Lifetime
- 2001-04-05 PT PT01940294T patent/PT1268480E/pt unknown
- 2001-04-05 SK SK1428-2002A patent/SK14282002A3/sk unknown
- 2001-04-05 WO PCT/EP2001/003909 patent/WO2001077110A1/fr not_active Ceased
- 2001-04-05 CZ CZ20023305A patent/CZ20023305A3/cs unknown
- 2001-04-05 DE DE60101158T patent/DE60101158T2/de not_active Expired - Lifetime
- 2001-04-05 DK DK01940294T patent/DK1268480T3/da active
- 2001-04-05 AU AU7392101A patent/AU7392101A/xx active Pending
- 2001-04-05 JP JP2001575583A patent/JP3869725B2/ja not_active Expired - Fee Related
- 2001-04-05 EP EP01940294A patent/EP1268480B1/fr not_active Expired - Lifetime
- 2001-04-05 IL IL15207801A patent/IL152078A0/xx unknown
- 2001-04-05 BR BR0109855-1A patent/BR0109855A/pt not_active IP Right Cessation
- 2001-04-05 KR KR10-2002-7012627A patent/KR100526094B1/ko not_active Expired - Fee Related
- 2001-04-05 AT AT01940294T patent/ATE253576T1/de active
- 2001-04-05 MX MXPA02009903A patent/MXPA02009903A/es active IP Right Grant
- 2001-04-05 CN CNB018074898A patent/CN1176922C/zh not_active Expired - Fee Related
- 2001-04-05 AU AU2001273921A patent/AU2001273921B2/en not_active Ceased
- 2001-04-05 PL PL358205A patent/PL212407B1/pl unknown
- 2001-04-05 PE PE2001000317A patent/PE20020228A1/es not_active Application Discontinuation
- 2001-04-05 AR ARP010101623A patent/AR028531A1/es not_active Application Discontinuation
- 2001-04-05 RU RU2002129557/04A patent/RU2269529C2/ru not_active IP Right Cessation
- 2001-04-05 MY MYPI20011632A patent/MY119238A/en unknown
- 2001-04-05 US US10/240,481 patent/US20030171384A1/en not_active Abandoned
- 2001-04-05 HU HU0300565A patent/HUP0300565A3/hu unknown
- 2001-04-05 TR TR2004/00185T patent/TR200400185T4/xx unknown
- 2001-04-05 CA CA002403514A patent/CA2403514C/fr not_active Expired - Fee Related
- 2001-04-05 NZ NZ521361A patent/NZ521361A/en unknown
2002
- 2002-10-02 NO NO20024741A patent/NO20024741L/no not_active Application Discontinuation
- 2002-10-03 ZA ZA200207956A patent/ZA200207956B/en unknown

Also Published As

Publication number	Publication date
EP1268480A1 (fr)	2003-01-02
AU7392101A (en)	2001-10-23
JP3869725B2 (ja)	2007-01-17
NZ521361A (en)	2004-05-28
NO20024741D0 (no)	2002-10-02
SK14282002A3 (sk)	2003-04-01
CN1420887A (zh)	2003-05-28
HUP0300565A3 (en)	2004-10-28
RU2002129557A (ru)	2004-03-27
DE60101158D1 (en)	2003-12-11
EP1268480B1 (fr)	2003-11-05
WO2001077110A1 (fr)	2001-10-18
CA2403514A1 (fr)	2001-10-18
CA2403514C (fr)	2010-01-12
ATE253576T1 (de)	2003-11-15
PT1268480E (pt)	2004-03-31
AU2001273921B2 (en)	2005-05-05
ES2210169T3 (es)	2004-07-01
US20030171384A1 (en)	2003-09-11
NO20024741L (no)	2002-10-02
HUP0300565A2 (hu)	2003-07-28
MY119238A (en)	2005-04-30
DE60101158T2 (de)	2004-08-26
IL152078A0 (en)	2003-05-29
CN1176922C (zh)	2004-11-24
AR028531A1 (es)	2003-05-14
GB0008694D0 (en)	2000-05-31
JP2003530398A (ja)	2003-10-14
ZA200207956B (en)	2003-07-16
PL212407B1 (pl)	2012-09-28
RU2269529C2 (ru)	2006-02-10
TR200400185T4 (tr)	2004-03-22
PL358205A1 (en)	2004-08-09
KR100526094B1 (ko)	2005-11-08
PE20020228A1 (es)	2002-03-28
BR0109855A (pt)	2003-06-03
MXPA02009903A (es)	2003-03-27
CZ20023305A3 (cs)	2003-01-15
KR20020081590A (ko)	2002-10-28

Publication	Publication Date	Title
NO20024741D0 (no)	2002-10-02	8-quinolinxantin og 8-isoquinolinxantinderivater som PDE5- inhibitorer
ATE433451T1 (de)	2009-06-15	Xanthin-phosphodiesteras-v-inhibitoren
NO20023713D0 (no)	2002-08-06	2-benzotiazolyl-urea-derivater samt anvendelse derav som proteinkinaseinhibitorer
DK1289985T3 (da)	2004-04-05	Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
ATE325807T1 (de)	2006-06-15	Purinderivate
NO20021239L (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
DK1317442T3 (da)	2006-02-13	Quinolinonderivater som tyrosinkinaseinhibitorer
ATE267836T1 (de)	2004-06-15	Purinderivate
NO20026010L (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20030146D0 (no)	2003-01-10	Pyrimidin-derivater
IL181957A0 (en)	2009-02-11	Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
DK1337527T3 (da)	2010-01-04	Indolylmaleinimidderivater som proteinkinase C-inhibitorer
EE200300085A (et)	2004-12-15	Pürasooli derivaadid ja nende kasutamine proteiini kinaasi inhibiitoritena
ATE278690T1 (de)	2004-10-15	Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DK1226143T3 (da)	2003-06-30	Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20021959L (no)	2002-05-29	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
ATE390425T1 (de)	2008-04-15	Xanthin-phosphodiesterase-v-hemmer polymorphe
DK1222193T3 (da)	2003-12-01	Imidazolderivater som phosphodiesterase VII-inhibitorer
NO20025884D0 (no)	2002-12-06	2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
DE50104434D1 (de)	2004-12-09	Lactam-substituierte pyrazolopyridinderivate
DK1296981T3 (da)	2005-07-25	Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer